Northwest Biotherapeutics annual asset turnover
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Northwest Biotherapeutics Asset Turnover Growth & History (NWBO)
Northwest Biotherapeutics's asset turnover was 0.03 for fiscal 2025.
View full Northwest Biotherapeutics company overviewNorthwest Biotherapeutics annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.03 | −0.03 | −49.61% |
| 2024 | 2024-12-31 | 0.05 | −0.01 | −22.45% |
| 2023 | 2023-12-31 | 0.07 | 0.02 | +38.64% |
| 2022 | 2022-12-31 | 0.05 | 0.02 | +71.15% |
| 2021 | 2021-12-31 | 0.03 | −0.03 | −53.60% |
| 2020 | 2020-12-31 | 0.06 | −0.08 | −56.56% |
| 2019 | 2019-12-31 | 0.14 | 0.13 | +1118.84% |
| 2018 | 2018-12-31 | 0.01 | 0.00 | +69.68% |
| 2017 | 2017-12-31 | 0.01 | −0.00 | −34.47% |
| 2016 | 2016-12-31 | 0.01 | −0.02 | −63.15% |
| 2015 | 2015-12-31 | 0.03 | −0.01 | −29.28% |
| 2014 | 2014-12-31 | 0.04 | −0.02 | −37.05% |
| 2013 | 2013-12-31 | 0.06 | −0.14 | −69.06% |
| 2012 | 2012-12-31 | 0.20 | 0.16 | +401.97% |
| 2011 | 2011-12-31 | 0.04 | — | — |
Northwest Biotherapeutics quarterly asset turnover
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.04 | 0.00 | +8.78% |
| Q1 2026 | 2026-03-31 | 0.03 | −0.02 | −47.02% |
| Q4 2025 | 2025-12-31 | 0.03 | −0.03 | −49.61% |
| Q3 2025 | 2025-09-30 | 0.03 | −0.02 | −40.43% |
| Q2 2025 | 2025-06-30 | 0.04 | −0.02 | −34.77% |
| Q1 2025 | 2025-03-31 | 0.05 | 0.01 | +20.81% |
| Q4 2024 | 2024-12-31 | 0.05 | −0.01 | −22.45% |
| Q3 2024 | 2024-09-30 | 0.05 | −0.01 | −21.18% |
| Q2 2024 | 2024-06-30 | 0.06 | −0.01 | −13.77% |
| Q1 2024 | 2024-03-31 | 0.04 | −0.02 | −36.04% |
| Q4 2023 | 2023-12-31 | 0.07 | 0.02 | +38.64% |
| Q3 2023 | 2023-09-30 | 0.07 | 0.03 | +81.87% |
| Q2 2023 | 2023-06-30 | 0.07 | 0.02 | +54.07% |
| Q1 2023 | 2023-03-31 | 0.07 | 0.03 | +83.58% |
| Q4 2022 | 2022-12-31 | 0.05 | 0.02 | +71.15% |
| Q3 2022 | 2022-09-30 | 0.04 | −0.02 | −32.70% |
| Q2 2022 | 2022-06-30 | 0.04 | −0.02 | −30.54% |
| Q1 2022 | 2022-03-31 | 0.04 | −0.01 | −19.66% |
| Q4 2021 | 2021-12-31 | 0.03 | −0.03 | −53.60% |
| Q3 2021 | 2021-09-30 | 0.05 | −0.04 | −39.69% |
| Q2 2021 | 2021-06-30 | 0.06 | −0.08 | −54.82% |
| Q1 2021 | 2021-03-31 | 0.05 | −0.11 | −70.62% |
| Q4 2020 | 2020-12-31 | 0.06 | −0.08 | −56.56% |
| Q3 2020 | 2020-09-30 | 0.09 | 0.05 | +139.87% |
| Q2 2020 | 2020-06-30 | 0.14 | 0.11 | +377.20% |
| Q1 2020 | 2020-03-31 | 0.16 | 0.14 | +841.32% |
| Q4 2019 | 2019-12-31 | 0.14 | 0.13 | +1118.84% |
| Q3 2019 | 2019-09-30 | 0.04 | 0.02 | +101.86% |
| Q2 2019 | 2019-06-30 | 0.03 | 0.02 | +137.10% |
| Q1 2019 | 2019-03-31 | 0.02 | 0.01 | +104.44% |
| Q4 2018 | 2018-12-31 | 0.01 | 0.00 | +69.68% |
| Q3 2018 | 2018-09-30 | 0.02 | 0.01 | +145.14% |
| Q2 2018 | 2018-06-30 | 0.01 | 0.00 | +57.85% |
| Q1 2018 | 2018-03-31 | 0.01 | −0.00 | −0.93% |
| Q4 2017 | 2017-12-31 | 0.01 | −0.00 | −34.47% |
| Q3 2017 | 2017-09-30 | 0.01 | −0.02 | −72.99% |
| Q2 2017 | 2017-06-30 | 0.01 | −0.02 | −70.80% |
| Q1 2017 | 2017-03-31 | 0.01 | −0.02 | −74.20% |
| Q4 2016 | 2016-12-31 | 0.01 | −0.02 | −63.15% |
| Q3 2016 | 2016-09-30 | 0.03 | −0.02 | −34.78% |
| Q2 2016 | 2016-06-30 | 0.03 | −0.03 | −49.69% |
| Q1 2016 | 2016-03-31 | 0.03 | −0.02 | −40.05% |
| Q4 2015 | 2015-12-31 | 0.03 | −0.01 | −29.28% |
| Q3 2015 | 2015-09-30 | 0.04 | 0.01 | +37.25% |
| Q2 2015 | 2015-06-30 | 0.05 | −0.00 | −0.38% |
| Q1 2015 | 2015-03-31 | 0.05 | −0.05 | −48.39% |
| Q4 2014 | 2014-12-31 | 0.04 | −0.02 | −37.05% |
| Q3 2014 | 2014-09-30 | 0.03 | −0.25 | −88.79% |
| Q2 2014 | 2014-06-30 | 0.05 | −0.44 | −89.18% |
| Q1 2014 | 2014-03-31 | 0.10 | −2.33 | −95.76% |
| Q4 2013 | 2013-12-31 | 0.06 | −0.14 | −69.06% |
| Q3 2013 | 2013-09-30 | 0.28 | −0.11 | −27.65% |
| Q2 2013 | 2013-06-30 | 0.49 | 0.41 | +468.18% |
| Q1 2013 | 2013-03-31 | 2.43 | 2.40 | +6227.71% |
| Q4 2012 | 2012-12-31 | 0.20 | — | — |
| Q3 2012 | 2012-09-30 | 0.39 | — | — |
| Q2 2012 | 2012-06-30 | 0.09 | — | — |
| Q1 2012 | 2012-03-31 | 0.04 | — | — |
Northwest Biotherapeutics asset turnover trends
Over the last five fiscal years, Northwest Biotherapeutics's asset turnover decreased from 0.06 to 0.03, a change of −0.03. The latest reported quarter, Q2 2026, shows 0.04.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Northwest Biotherapeutics source filings ↗